FDA approves first drug targeting full range of narcolepsy type 1 symptoms

The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults. The drug, developed by Takeda Pharmaceuticals, is the first approved therapy to directly target the loss of orexin signaling, the biological mechanism underlying the condition.

The approval is based on data from two randomized, double-blind, placebo-controlled studies involving a total of 273 adults with narcolepsy type 1. Over a 12-week period, patients taking a 2 mg dose of Orzeyful demonstrated statistically significant improvements in their ability to stay awake during the day compared with those receiving a placebo.

Participants also reported a significant reduction in cataplexy episodes, which are sudden losses of muscle tone triggered by strong emotions. The trials recorded meaningful improvements in other core symptoms as well, including sleep paralysis, hallucinations, and disrupted nighttime sleep.

Common side effects observed in the studies included insomnia, increased urinary frequency, urgency to urinate, and increased saliva production. The FDA's Center for Drug Evaluation and Research noted that previous treatments addressed only individual symptoms of the complex, lifelong neuropsychiatric condition.

"For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it," said Tiffany R. Farchione, MD, of the FDA Center for Drug Evaluation and Research. "This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole."

Narcolepsy type 1 is caused by a deficiency of orexin, a neuropeptide that regulates wakefulness and sleep stability. By targeting this specific pathway, Orzeyful represents a mechanistic advance over existing therapies that manage symptoms without addressing the root cause.

The approval provides a new therapeutic option for adults living with the disorder, which affects an estimated 25 to 50 people per 100,000 worldwide. Long-term safety and efficacy data beyond the 12-week trial period will continue to be collected through post-marketing surveillance.